A series of 64 cases of pancreatic cystic neoplasia from an institutional study of China

Table 1 Antibodies used for immunostaining of cystic neoplasia of the pancreas

Antibody	Clone	Type	Producer	Dilution	Commence
PanCK	AE1/AE3	MoAb	DAKO	1:100	Membrane
CK 7	OV-TL	MoAb	DAKO	1:200	Membrane
CK 8/18	RCK108	MoAb	DAKO	1:200	Membrane
CA19-9	116-NS-19-9	MoAb	DAKO	1:50	Cytoplasmic
CEA	A0115	PoAb	DAKO	1:200	Cytoplasmic
EMA	E29	MoAb	DAKO	1:100	Membrane
MUC1	Ma695	MoAb	Novacastra	1:100	Apical membrane
MUC2	Ccp58	MoAb	Novacastra	1:1000	Cytoplasmic
MUC4		MoAb	Zymed	1:100	Apical membrane
MUC5AC	CLH2	MoAb	Novacastra	1:1000	Cytoplasmic
MUC6	CLH5	MoAb	Novacastra	1:100	Cell membrane
Synaptophysin		MoAb	DAKO	1:100	Cytoplasmic
Chromogranin-A	DAK-A3	MoAb	DAKO	1:20	Cytoplasmic
NSE		PoAb	DAKO	1:200	Cytoplasmic
α1-AT		PoAb	DAKO	1:500	Cytoplasmic
α1-ACT		PoAb	DAKO	1:250	Cytoplasmic
Vimentin	V9	MoAb	DAKO	1:100	Cytoplasmic
α-inhibin		MoAb	DAKO	1:50	Nuclear
β-catenin		MoAb	DAKO	1:100	Membrane/ nuclear

CK: cytokeratin; CEA: carcinoma-embryonal antigen; EMA: epithelial membrane antigen; NSE: neural specific enolase; α1-AT: alpha-1-antitrypsin; α1-ACT: alpha-1-antichymotrypsin.

Table 2 Distribution of 64 cases of cystic neoplasia of the pancreas

Type		n	Percentage
Intraductal papillary mucinous neoplasia		28	43.8
	Adenoma	5
	Borderline	4
	Carcinoma	19
Serous cystic neoplasia		12	18.8
	Adenoma	11
	Borderline	0
	Carcinoma	1
Mucinous cystic neoplasia		11	17.3
	Adenoma	8
	Borderline	1
	Carcinoma	2
Solid pseudo-papillary neoplasia	Borderline (Uncertain malignant potential)	11	17.3
Cystic ductal adenocarcinoma	High-grade malignant	1	1.6
Cystic pancreas endocrine tumor	Low-grade malignant	1	1.6
Total		64	100

Table 3 Clinicopathologic data of 40 cases of cystic neoplasia of the pancreas

Clinical feature	Type	IPMN n = 28	SCN n =12	MCN n =11	SPN n =11	cDAC n =1	cPET n =1
Age (yr)	Mean (range)	65 (45-80)	52.7 (36-69)	51.7 (29-72)	39 (22-52)	58	45
Sex	Male:Female	4:3	3:10	1:10	1:10	1:0	1:0
Location	Head	16	5	2	3	1	1
	Body/tail	12	7	9	8
Tumor size	Range (mean)	2-7.5 (4.5)	3-12 (6)	2-13 (7.8)	2-21 (6.5)	5	4.5

IPMN: intraductal papillary mucinous neoplasia; SCN: serous cystic neoplasia; MCN: mucinous cystic neoplasia; SPN: solid pseudo-papillary neoplasia; cDAC: cystic ductal adenocarcinoma; cPET: cystic pancreatic endocrine tumor.

Table 4 Immunoreactivity of cystic neoplasia of the pancreas

Type	IPMNn = 28	SCNn = 12	MCNn = 11	SPNn = 11	cDACn = 1	cPETn = 1
CK8/18	+	+	+	-	+	+
CK19	++	+	+	-	+	+/-
CA19-9	+	-	+/-	-	+	-
CEA	+	-	-/+	-	+	-
SYN	+/-	-	+/-	+/-	-	+
CHG-A	+/-	-	+/-	-	-	+
NSE	+	+/-	+/-	+
α-AT	-	-	-	+	-	-
α-ACT	-	-	-	+	-	-
Vim	-	-		+	-	-
α-inhibin	-	+	+1	+/-
β-catenin	-	+	-	+/-	-	-

¹Positive α-inhibin in MCN is limited in ovarian-like stromal cells. IPMN: intraductal papillary mucinous neoplasia; SCN: serous cystic neoplasia; MCN: mucinous cystic neoplasia; SPN: solid pseudo-papillary neoplasia; cDAC: cystic ductal adenocarcinoma; cPET: cystic pancreatic endocrine tumor.

Table 5 Mucin profiles of cystic neoplasia of the pancreas

Type	IPMNn = 28	SCNn = 12	MCNn = 11	SPNn = 11	cDACn = 1	cPETn = 1
MUC1	7/28 +	1/12 +/-	2/11 +	-	++	-
MUC2	15/28 ++	1/13 +/-	-	-	-	-
MUC4	-	-	--	-	++
MUC5AC	28/28 +	2/12 +	10/11 ++	-	+	-
MUC6	-	11/12 ++	-	-	+	-

IPMN: intraductal papillary mucinous neoplasia; SCN: serous cystic neoplasia; MCN: mucinous cystic neoplasia; SPN: solid pseudo-papillary neoplasia; cDAC: cystic ductal adenocarcinoma; cPET: cystic pancreas endocrine tumor.